Document Type : Original Article(s)


1 MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran


Background: Prostate cancer remains one of the most common and lethal cancers among men worldwide. This study aimed to investigate the characteristics, prognostic factors, and outcomes of patients with prostate cancer who were treated and followed up in Shiraz, southern Iran over the past 12 years.
Method: This retrospective medical chart review was performed on 872 patients with prostate cancer who were treated and followed up in the Radiation Oncology Department of Shiraz University of Medical Sciences. The survival analysis was conducted for the patients, and the receiver operating characteristic (ROC) curve analysis was performed for the prostate-specific antigen (PSA) level.
Results: The median age of the patients at presentation was 69 years (range 35-91 years). In terms of local treatments, 28% of the patients underwent prostatectomy, and 23% were treated with transurethral resection of the prostate. The remaining 49% of patients were treated with non-surgical therapies. Patients between 55 and 75 years had the longest survival duration. The shortest survival was observed in the third Gleason group and those over 75 years old, while the first Gleason group and patients younger than 55 years had the longest survival duration. Hypoalbuminemia had no effect on the survival duration. A PSA level of 33.8 ng/dl was the most suitable cutoff point to predict bone metastasis, and patients with a PSA level of more than 33.8 ng/dl had significantly less survival duration than the others.
Conclusion: More aggressive treatment and shorter follow-up intervals are recommended for patients with an initial PSA level of more than 33.8 and those younger than 55 years old.


Alireza Salehi (Google Scholar)


How to cite this article:

Sepahvand M, Salehi A, Omidvari A, Omidvari S, Mohammadianpanah M. Prostate cancer survival analysis of 872 patients in southern Iran: a retrospective cohort study. Middle East J Cancer. 2023;14(4):570-7. doi: 10.30476/mejc.2023.95281.1763.

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020;70(4):313.
  2. Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388-400. doi: 10.1002/ijc.29894.
  3. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618-29. doi: 10.1016/j.eururo.2016.08.003.
  4. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-87. doi: 10.1016/j.ejca.2018.07.005.
  5. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.
  6. Schröder FH, Kruger AB, Rietbergen J, Kranse R, Maas Pvd, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst. 1998;90(23):1817-23. doi: 10.1093/jnci/90.23.1817.
  7. Woolf SH. Screening for prostate cancer with prostate-specific antigen—an examination of the evidence. N Engl J Med.1995;333(21):1401-5. doi: 10.1056/NEJM199511233332107.
  8. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol.1992;23(3):273-9.  doi: 10.1016/0046-8177(92)90108-f.
  9. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA.1997;277(18):1445-51. doi:10.1001/jama.1997.03540420041027.
  10. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol.2015;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001.
  11. Grönberg H, Damber J-E, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol.1994;152(3):892-5.  doi: 10.1016/s0022-5347(17)32601-0.
  12. Iwamoto H, Izumi K, Kadono Y, Mizokami A. Prognosis of patients with prostate cancer and middle range prostate-specific antigen levels of 20–100 ng/mL. Int Braz J Urol.2019;45(1):61-7. doi: 10.1590/S1677-5538.IBJU.2018.0143.
  13. Sejima T, Iwamoto H, Masago T, Morizane S, Yao A, Isoyama T, et al. Low pre–operative levels of serum albumin predict lymph node metastases and ultimately correlate with a biochemical recurrence of prostate cancer in radical prostatectomy patients. Cent European J Urol. 2013;66(2):126-32. doi: 10.5173/ceju.2013.02.art3. 
  14. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277(6):467-71. Erratum in: JAMA. 1997;278(3):206.
  15. Akbari ME, Hosseini SJ, Rezaee A, Hosseini MM, Rezaee I, Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev.2008;9(4):549-52.
  16. Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate cancer in Iran: trends in incidence and morphological and epidemiological characteristics. Asian Pac J Cancer Prev.2016;17(2):839-43. doi: 10.7314/apjcp.2016.17.2.839.
  17. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer.2000;85(1):60-7. doi: 10.1002/(sici)1097-0215(20000101)85:1<60::aid-ijc11>;2-b.
  18. Polyakov S, Yaumenenka A. Survival in patients with locally advanced prostate cancer: A population-based study. European Urology Supplements. 2017;16(5):e2219. doi: 10.1016/S1569-9056(17)31362-3
  19. da Cruz JAS, Passerotti CC, Dos Reis ST, Guariero MES, de Campos OD, Leite KRM, et al. Is Age an independent factor for prostate cancer? A paired analysis. Curr Urol.2017;9(4):183-7. doi: 10.1159/000447138. 
  20. Wang N, Liu JY, Li X, Deng MH, Long Z, Tang J, et al. Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade. Asian J Androl. 2018;21(1):56-61. doi: 10.4103/aja.aja_50_18.
  21. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med.2004;116 Suppl 7A:11S-26S. doi: 10.1016/j.amjmed.2003.12.008.
  22. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25(3 Suppl 7):43-6.
  23. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer. 2001;91(12):2214-21. doi: 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P.